Filament Health, a subsidiary of Rhelion Life Sciences, has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to provide more of its botanical psilocybin drug candidate, PEX010, for the TEMPO clinical trial on treatment-resistant depression in Italy. The trial, authorized under the EU Clinical Trials Regulation, increased participant numbers, prompting the need for more PEX010 capsules. Filament also supports regulatory processes and supplies standardized doses to ensure consistency. This expansion highlights growing clinical research into psilocybin's therapeutic potential and Filament's role as a leading supplier in this emerging sector.
Filament Health's expanded supply agreement for PEX010 in the TEMPO clinical trial is the story's focus, with Pluang data showing 55 of 100 Health-sector US stocks rose while 37 fell. Notable movers include AMWL at USD 13.21 with a -1.93% change and a typical hold time of 61 days, TXG at USD 85.70 up 1.89% with 40% sell and 60% buy order activity and a 94-day hold, and CYTK at USD 64.50 down 1.77% with an 18-day hold. These figures are as of Sep 25, 2026 18:42 WIB.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
